Roche Pharmaceutical Development and Sales Overview

TNKaseⓇ (RG3625, tenecteplase) Small molecule tissue plasminogen activator Indication Phase/study # of patients Design Stroke patients between 4.5 and 24 hours Phase III TIMELESS N=456 ■ ☐ ARM A: Tenecteplase (0.25 mg/kg, maximum 25 mg) single bolus injection ARM B: Placebo Primary endpoint Ordinal modified Rankin scale (mRS) score after 90 days FPI Q1 2019 Status CT Identifier NCT03785678 128 Roche Neuroscience

View entire presentation